A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Elobixibat Impurity 7 - Request Quote

Picture of Elobixibat Impurity 7

Elobixibat Impurity 7

SZ CAT No:SZ-E072023
CAS No
NA
Mol.F.
C35H43N3O7S2
Mol.Wt.
681.9
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Elobixibat Impurity 7 is chemically (2-(2-((3,3-Dibutyl-7-mercapto-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetyl)glycine. Elobixibat Impurity 7 is supplied with detailed characterization data compliant with regulatory guideline. Elobixibat Impurity 7 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Elobixibat.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Elobixibat Impurity 7

Purchase Elobixibat Impurity 7

Elobixibat Impurity 7 suppliers

Elobixibat Impurity 7 manufacturers

Elobixibat Impurity 7 price

Order Elobixibat Impurity 7

Enquire Elobixibat Impurity 7

Elobixibat Impurity 7 cost

Elobixibat Impurity 7 Supplier

Elobixibat Impurity 7 Distributor

Elobixibat Impurity 7 for Method Validation

Elobixibat Reference Standard

Elobixibat Impurity 7 for ANDA Filing

Elobixibat Impurity 7 for Forced Degradation Studies

Elobixibat Impurity 7 Identification Standards

Elobixibat Impurity 7 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,